Imaging of Chemotherapy-Induced Acute Cardiotoxicity with
Animals
Antineoplastic Agents
/ adverse effects
Cardiotoxicity
/ diagnostic imaging
Doxorubicin
/ adverse effects
Fluorine Radioisotopes
Hydrophobic and Hydrophilic Interactions
Isotope Labeling
Male
Organophosphorus Compounds
/ chemistry
Positron-Emission Tomography
Rats
Rats, Sprague-Dawley
Tissue Distribution
18F radiochemistry
PET
cardiotoxicity
doxorubicin
phosphonium cations
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
11
02
2019
accepted:
29
05
2019
pubmed:
31
5
2019
medline:
1
7
2020
entrez:
1
6
2019
Statut:
ppublish
Résumé
Many chemotherapy agents are toxic to the heart, such that increasing numbers of cancer survivors are now living with the potentially lethal cardiovascular consequences of their treatment. Earlier and more sensitive detection of chemotherapy-induced cardiotoxicity may allow improved treatment strategies and increase long-term survival. Lipophilic cation PET tracers may be suitable for early detection of cardiotoxicity. This study aimed to evaluate an
Identifiants
pubmed: 31147403
pii: jnumed.119.226787
doi: 10.2967/jnumed.119.226787
pmc: PMC6894381
doi:
Substances chimiques
Antineoplastic Agents
0
Fluorine Radioisotopes
0
Organophosphorus Compounds
0
Doxorubicin
80168379AG
Fluorine-18
GZ5I74KB8G
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1750-1756Subventions
Organisme : British Heart Foundation
ID : PG/16/43/32141
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
Pays : United Kingdom
Informations de copyright
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.
Références
J Nucl Med. 2001 Aug;42(8):1166-73
pubmed: 11483675
Circulation. 2015 Jun 2;131(22):1981-8
pubmed: 25948538
J Nucl Med. 2004 May;45(5):842-8
pubmed: 15136635
Cancer. 1973 Aug;32(2):302-14
pubmed: 4353012
Eur J Pharmacol. 2003 Apr 4;465(3):275-80
pubmed: 12681439
Eur J Pharmacol. 2018 Jan 5;818:241-253
pubmed: 29074412
EJNMMI Res. 2013 Nov 14;3(1):74
pubmed: 24225195
Arch Toxicol. 2016 Sep;90(9):2063-2076
pubmed: 27342245
J Nucl Med. 1995 Jun;36(6):952-5
pubmed: 7769451
Mol Imaging Biol. 2011 Jun;13(3):511-517
pubmed: 20563755
J Nucl Med. 2007 Jun;48(6):1021-30
pubmed: 17504876
JACC Cardiovasc Imaging. 2018 Aug;11(8):1045-1055
pubmed: 30092965
Circ Heart Fail. 2016 Jan;9(1):e002661
pubmed: 26747861
Pharmacol Res. 2001 Mar;43(3):211-8
pubmed: 11401411
J Nucl Med. 2014 Mar;55(3):488-94
pubmed: 24421288
Circ Heart Fail. 2019 Mar;12(3):e005234
pubmed: 30871347
Molecules. 2017 Mar 30;22(4):
pubmed: 28358340
Pharm Biol. 2016;54(4):637-47
pubmed: 26471226
Cardiology. 2010;115(2):155-62
pubmed: 20016174
Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):2057-65
pubmed: 17786439
Ann Intern Med. 1974 Feb;80(2):249-59
pubmed: 4590654
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Mol Pharm. 2014 Nov 3;11(11):3818-22
pubmed: 25158244
J Nucl Med. 2007 Oct;48(10):1662-9
pubmed: 17873124
Eur J Cancer. 1995;31A(1):26-31
pubmed: 7695974
J Mol Cell Cardiol. 2012 Jun;52(6):1213-25
pubmed: 22465037
J Nucl Cardiol. 2012 Apr;19(2):377-88
pubmed: 22351492
Am J Transl Res. 2016 Jan 15;8(1):60-9
pubmed: 27069540
JACC Cardiovasc Imaging. 2014 Aug;7(8):824-38
pubmed: 25124015
J Nucl Med. 2011 Apr;52(4):560-71
pubmed: 21421717
J Labelled Comp Radiopharm. 2013 May 30;56(6):313-6
pubmed: 24285410
Ann Intern Med. 1979 Nov;91(5):710-7
pubmed: 496103
Sci Rep. 2019 Jan 18;9(1):216
pubmed: 30659226